Telix Pharmaceuticals

Melbourne, Australia Founded: 2015 • Age: 11 yrs
Theranostic radiopharmaceuticals are developed for cancer imaging and therapy.
Request Access

About Telix Pharmaceuticals

Telix Pharmaceuticals is a company based in Melbourne (Australia) founded in 2015. It operates as a Professional Services. Telix Pharmaceuticals has completed 9 acquisitions, including ANMI, ARTMS and ATLAB Pharma. Telix Pharmaceuticals offers products and services including Illuccix® and Gozellix®. Telix Pharmaceuticals operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, ImaginAb, Mariana Oncology and AdvanCell, among others.

  • Headquarter Melbourne, Australia
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Telix Pharmaceuticals Limited
Operational Areas
Healthcare → Medical Devices & Diagnostics
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $485.14 M (USD)
    55.85
    as on Dec 31, 2024
  • Net Profit
    $30.92 M (USD)
    857.95
    as on Dec 31, 2024
  • EBITDA
    $55.87 M (USD)
    54.36
    as on Dec 31, 2024
  • Latest Funding Round
    $25 M (USD), Post-IPO

    Nov 02, 2020

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
    ANMI

    & 8 more

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Telix Pharmaceuticals

Telix Pharmaceuticals is a publicly listed company on the ASX with ticker symbol TLX in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: ASX · Ticker: TLX . Sector: Health technology · Australia

Products & Services of Telix Pharmaceuticals

Telix Pharmaceuticals offers a comprehensive portfolio of products and services, including Illuccix® and Gozellix®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Used for prostate cancer imaging in diagnostics.

Employed for prostate cancer imaging and diagnosis.

People of Telix Pharmaceuticals
Headcount 50-200
Employee Profiles 68
Board Members and Advisors 15
Employee Profiles
People
Nabil Elshafeey
Medical Director Neuro And Rare Disease
People
Raphaël Ortiz
COO, EMEA
People
Jp Pal
Global Head Of Medtech, Digital & Ai/ml Marketing
People
Olga Pavlova
Director Global Regulatory Affairs

Unlock access to complete

Board Members and Advisors
people
Jason Lewis
Scientific Advisor
people
Tiffany Olson
Independent Non-Executive Director and Chair
people
Frederik Giesel
Scientific Advisor
people
Rodney Hicks
Scientific Advisor

Unlock access to complete

Funding Insights of Telix Pharmaceuticals

  • Total Funding
  • Total Rounds 1
  • Last Round Post-IPO — $25.0M
  • First Round

    (02 Nov 2020)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2020 Amount Post-IPO - Telix Pharmaceuticals Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Telix Pharmaceuticals

Telix Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include China Grand Pharmaceutical and Healthcare. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Finished formulations and APIs are manufactured for therapeutic categories.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Telix Pharmaceuticals

Telix Pharmaceuticals has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include ANMI, ARTMS and ATLAB Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Molecular imaging products and services are developed.
2018
AI-driven clinical decision support for diagnosis and therapy planning
2017
CDMO focused on synthesis of APIs
2015
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Telix Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Telix Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Telix Pharmaceuticals

Telix Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, ImaginAb, Mariana Oncology and AdvanCell, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Developer of molecular imaging systems and radio-pharmaceuticals
domain founded_year HQ Location
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
domain founded_year HQ Location
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
domain founded_year HQ Location
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
domain founded_year HQ Location
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Telix Pharmaceuticals

Frequently Asked Questions about Telix Pharmaceuticals

When was Telix Pharmaceuticals founded?

Telix Pharmaceuticals was founded in 2015 and raised its 1st funding round 5 years after it was founded.

Where is Telix Pharmaceuticals located?

Telix Pharmaceuticals is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.

What is the annual revenue of Telix Pharmaceuticals?

Annual revenue of Telix Pharmaceuticals is $485.14M as on Dec 31, 2024.

What does Telix Pharmaceuticals do?

Telix Pharmaceuticals is engaged in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, often referred to as theranostics. The companys extensive pipeline targets urologic oncology including prostate and kidney cancers, neuro-oncology such as glioma, musculoskeletal oncology like sarcoma, and bone marrow conditioning. Operations are supported by a robust global supply, manufacturing, and distribution network. Multiple clinical trials are conducted worldwide, with key products like Illuccix receiving regulatory approvals in various regions for prostate cancer imaging.

Who are the top competitors of Telix Pharmaceuticals?

Telix Pharmaceuticals's top competitors include Advanced Accelerator Applications, ImaginAb and SOFIE.

What products or services does Telix Pharmaceuticals offer?

Telix Pharmaceuticals offers Illuccix® and Gozellix®.

Is Telix Pharmaceuticals publicly traded?

Yes, Telix Pharmaceuticals is publicly traded on ASX under the ticker symbol TLX.

How many acquisitions has Telix Pharmaceuticals made?

Telix Pharmaceuticals has made 9 acquisitions, including ANMI, ARTMS, and ATLAB Pharma.

Who are Telix Pharmaceuticals's investors?

Telix Pharmaceuticals has 1 investor. Key investors include China Grand Pharmaceutical and Healthcare.

What is Telix Pharmaceuticals's ticker symbol?

The ticker symbol of Telix Pharmaceuticals is TLX on ASX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available